InnoVec Biotherapeutics Secures Tens of Millions in Series A+ Financing Led by Tianchuang Capital

Investment界 (ID: pedaily2012) June 12th news, recently, InnoVec Biotherapeutics Inc. (hereinafter referred to as "Innovecbio")Completed tens of millions ofA+Round Financing, this round of investment was led byTianchuang CapitalLeading investment,New investors and existing shareholdersFollow-on investment. The funds raised will be mainly used for the clinical validation and advancement of the company's product pipeline, as well as innovation in the gene delivery platform. This is reportedly one of the few financing events in the adeno-associated virus (AAV) gene therapy drug sector this year.

InnoVec Biotherapeutics Inc. (Innovecbio) is a clinical-stage gene therapy company driven by vector innovation. The company is committed to developing gene therapy delivery tools suitable for human use, addressing the challenges of translating delivery tools from animals to humans. Its goal is to discover gene delivery tools for all tissues and organs, enabling gene therapy to be widely applied to both rare and common diseases. InnoVec Biotherapeutics boasts highly efficient teams in technology development, pipeline research, process optimization, and clinical operations. It has established a leading technology development platform covering multiple disease areas such as ophthalmology, neurology, and muscular conditions. Several innovative products have already entered the IIT and IND stages.

Dr. Fan Tu, Managing Director of Tianchuang CapitalIt is believed that AAV is the most important vector form in the field of gene therapy, with great application prospects and advantages in both local and systemic administration. With China's engineering capabilities, it may be possible to make gene therapy, previously an overseas "astronomically priced drug," more affordable, truly benefiting a large number of patients with genetic diseases. Although large multinational pharmaceutical companies such as Pfizer, Vertex, and Takeda have abandoned their AAV gene therapy drug pipelines, other companies like Roche, Eli Lilly, and Novartis have introduced new AAV vector technologies. These events highlight the limitations of older AAV vectors in clinical applications and the strong demand for new AAV vectors in clinical settings. Innovecbio (InnoVec Biotherapeutics Inc.) is one of the few enterprises in China with a research and development system for new AAV vectors, and it is expected to address broader clinical needs, becoming a leading enterprise in this field both domestically and internationally.